Related references
Note: Only part of the references are listed.9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP-1 Release in T2D Patients and Is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta-Cell Function
Li Chen et al.
DIABETES (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans
Franz M. Matschinsky et al.
FRONTIERS IN PHYSIOLOGY (2019)
Dorzagliatin Differentiates from Early Generation of Glucokinase Activators: An Enzyme Kinetics Study
Li Chen et al.
DIABETES (2019)
No Drug-Drug Interaction between Dorzagliatin and Metformin in Type 2 Diabetes Patients
Li Chen et al.
DIABETES (2018)
Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
Xiao-Xue Zhu et al.
DIABETES OBESITY & METABOLISM (2018)
Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
Dalong Zhu et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
The mechanisms of action of metformin
Graham Rena et al.
DIABETOLOGIA (2017)
AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes
L. Katz et al.
DIABETES OBESITY & METABOLISM (2016)
Effects of Piragliatin, a Glucokinase Activator, on Fasting and Postprandial Plasma Glucose in Patients With Type 2 Diabetes Mellitus
Jianguo Zhi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes
N. B. Amin et al.
DIABETES OBESITY & METABOLISM (2015)
Decreased expression of hepatic glucokinase in type 2 diabetes
Rebecca A. Haeusler et al.
MOLECULAR METABOLISM (2015)
A Fresh View of Glycolysis and Glucokinase Regulation: History and Current Status
Sigurd Lenzen
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Early therapy for type 2 diabetes in China
Wenying Yang et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus
A. Kiyosue et al.
DIABETES OBESITY & METABOLISM (2013)
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2013)
Regulation of Glucagon Secretion in Normal and Diabetic Human Islets by γ-Hydroxybutyrate and Glycine
Changhong Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
Gary E. Meininger et al.
DIABETES CARE (2011)
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study
Riccardo C. Bonadonna et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Defining and Characterizing the Progression of Type 2 Diabetes
Vivian A. Fonseca
DIABETES CARE (2009)
Assessing the potential of glucokinase activators in diabetes therapy
Franz M. Matschinsky
NATURE REVIEWS DRUG DISCOVERY (2009)
Allosteric activators of glucokinase: Potential role in diabetes therapy
J Grimsby et al.
SCIENCE (2003)
Regulation of pancreatic β-cell glucokinase -: From basics to therapeutics
FM Matschinsky
DIABETES (2002)
Share Paper
